R&D Centers

R&D Center in China

Key R&D Capabilities

Long-acting and Extended Release Technology

Liposome and Targeted Drug Delivery Technology

NME Platforms

Biological Antibody Technology

Innovative Medical Technology

R&D Center in the U.S.

Key R&D Capabilities

International R&D Collaboration

Exploratory Study for Innovative Drugs

 

R&D Center in Europe

Key R&D Capabilities

Transdermal Drug Delivery Technology

Granted Patents

271 patents granted in China

508 patents granted overseas

(As of December 2023)

Platforms and Technologies

Novel Drug Delivery Systems (NDDS)& New Molecular Entity(NME)Platforms

Novel Drug Delivery Systems(NDDS):

Long-acting and extended release technology,

Liposome and targeted drug delivery technology,

Transdermal drug delivery technology;

Novel Drug Delivery Systems (NDDS)& New Molecular Entity(NME)Platforms

New Molecular Entity (NME) Platforms:

NCE platform: new chemical entity based on innovative targets,including novel small molecule compounds and biologics such as antibodies and nucleic acids; NTE platform: novel therapeutic entities with molecular modifications;PDC platform: peptide-conjugated drugs; Key capabilities set up for target discovery, drug design, screening and evaluation, contributing 10+ candidate drugs to the pipeline;

Antibodies

Human Antibody Transgenic Mouse and Phage Display Technology Platform:

BA-huMab® platform: Directly generate human antibodies without need for humanization, which significantly accelerates antibody discovery process and decreases immunogenicity risk; Elicit an immune response quickly and produce a high antibody titer after immunization; Phage display technology platform: Efficient animal immunity technology; Mature phage library construction technology; High-throughput and diverse phage based panning strategies; Diverse evaluation capabilities for antibodies or antibody fragments;

Antibodies

Bispecific T-cell Engager Technology Platform:

Demonstrate high avidity with tumor target antigen by bivalent binding to achieve better drug efficacy; Demonstrate low affinity with T cells by monovalent binding to lower toxicity; Reduce CD3 antibody binding affinity, to significantly reduce the risk of CRS;

Antibodies

ADC Technology Platform:

Design, synthesize and screen the potential ADC linker-payload; Identification of potential internalized antibodies; Diverse antibody conjugation technologies; Evaluation of ADC in vitro and in vivo; Process development and quality analysis for ADC products;

Innovative Therapies

Nucleic Acid Therapy and Gene Therapy:

Research and development of novel therapies including AAV-based gene therapy and nucleic acid therapy (mRNA and Oligo). Both harbor significant potential to address a wide spectrum of diseases;

Innovative Therapies

Gene and Nucleic Acid Targeted Delivery:

Delivery is a critical enabling element in nucleic and gene therapy. The proprietary LNP platform adds value to the pipeline by enabling tissue and organ specific delivery;

Innovative Therapies

Cellular Immunotherapies:

Developing next-generation cell therapy technologies engineered to target neo-tumor antigens and accomplish other therapeutic functions. Novel non viral vector technology to enhance manufacturing efficiency. Improve cancer treatment by providing a personalized therapy option;

R&D Pipelines

R&D Centers

located in China, the United States
and Europe

Robust R&D pipelines of drug candidates:

30+ in China

10+ overseas


900+ R&D professionals

R&D Centers

R&D Center in the U.S.

Key R&D Capabilities

Exploratory Study for Innovative Drugs

International R&D Collaboration

R&D Center in China

Key R&D Capabilities

Long-acting and Extended Release Technology

Liposome and Targeted Drug Delivery Technology

NME Platforms

Biological Antibody Technology

Innovative Medical Technology

R&D Center in Europe

Key R&D Capabilities

Transdermal Drug Delivery Technology

Granted Patents

271 patents granted in China

508 patents granted overseas

(As of December 2023)

Platforms and Technologies

Novel Drug Delivery Systems (NDDS)& New Molecular Entity(NME)Platforms

Novel Drug Delivery Systems(NDDS):

Long-acting and extended release technology,

Liposome and targeted drug delivery technology,

Transdermal drug delivery technology;

Novel Drug Delivery Systems (NDDS)& New Molecular Entity(NME)Platforms

New Molecular Entity (NME) Platforms:

NCE platform: new chemical entity based on innovative targets,including novel small molecule compounds and biologics such as antibodies and nucleic acids; NTE platform: novel therapeutic entities with molecular modifications;PDC platform: peptide-conjugated drugs; Key capabilities set up for target discovery, drug design, screening and evaluation, contributing 10+ candidate drugs to the pipeline;

Antibodies

Human Antibody Transgenic Mouse and Phage Display Technology Platform:

BA-huMab® platform: Directly generate human antibodies without need for humanization, which significantly accelerates antibody discovery process and decreases immunogenicity risk; Elicit an immune response quickly and produce a high antibody titer after immunization; Phage display technology platform: Efficient animal immunity technology; Mature phage library construction technology; High-throughput and diverse phage based panning strategies; Diverse evaluation capabilities for antibodies or antibody fragments;

Antibodies

Bispecific T-cell Engager Technology Platform:

Demonstrate high avidity with tumor target antigen by bivalent binding to achieve better drug efficacy; Demonstrate low affinity with T cells by monovalent binding to lower toxicity; Reduce CD3 antibody binding affinity, to significantly reduce the risk of CRS;

Antibodies

ADC Technology Platform:

Design, synthesize and screen the potential ADC linker-payload; Identification of potential internalized antibodies; Diverse antibody conjugation technologies; Evaluation of ADC in vitro and in vivo; Process development and quality analysis for ADC products;

Innovative Therapies

Nucleic Acid Therapy and Gene Therapy:

Research and development of novel therapies including AAV-based gene therapy and nucleic acid therapy (mRNA and Oligo). Both harbor significant potential to address a wide spectrum of diseases;

Innovative Therapies

Gene and Nucleic Acid Targeted Delivery:

Delivery is a critical enabling element in nucleic and gene therapy. The proprietary LNP platform adds value to the pipeline by enabling tissue and organ specific delivery;

Innovative Therapies

Cellular Immunotherapies:

Developing next-generation cell therapy technologies engineered to target neo-tumor antigens and accomplish other therapeutic functions. Novel non viral vector technology to enhance manufacturing efficiency. Improve cancer treatment by providing a personalized therapy option;

R&D Pipelines

Overseas R&D Pipelines
R&D Pipelines in China